Director purchases 1,000 shares of $STZ

An insider purchase was recently reported at $STZ, where Director Christopher J Baldwin acquired 1,000 shares of the company on 07-07-2025 at an approximate cost of $171,266. This transaction, as identified by Quiver Quantitative from an SEC filing, expanded Baldwin’s stake in this category of stock by around 480.8%. Following this acquisition, Baldwin now possesses 1,208 shares of $STZ stock.

The insider trading activity at $STZ has seen insiders engage in four trades over the past half-year. Out of these transactions, three were purchases, and one was a sale. Notably, EVP & President of Wine and Spirits, Samuel J Glaetzer, divested 3,150 shares for an estimated sum of $593,901. Conversely, apart from the recent purchase by Baldwin, William T Giles also made a substantial acquisition of 1,000 shares, amounting to $186,390.

Furthermore, hedge fund involvement with $STZ has witnessed 464 institutional investors augment their shares in the company, while 792 reduced their positions in the last quarter. Some of the significant recent movements in hedge fund portfolios include Berkshire Hathaway Inc increasing its stake by 6,384,676 shares (representing a 113.5% rise) in Q1 2025, valued at approximately $1,171,715,739. Conversely, Morgan Stanley shed 4,741,716 shares (or 58.9%) from their holdings in the same period, totaling around $870,199,720.

Moreover, members of Congress have engaged in five trades involving $STZ stock in the past six months, with one purchase and four sales made. One of the trades saw Senator Tommy Tuberville selling up to $50,000 on 04/15. In contrast, Representative Robert Bresnahan acquired up to $15,000 worth of $STZ stock on 04/08. Notably, Representative Julie Johnson conducted two sales on 04/01 and 01/15, totaling up to $30,000, while Senator Markwayne Mullin divested up to $50,000 on 02/13.

Analyst ratings from Wall Street have unveiled favorable sentiment towards $STZ, with nine firms issuing buy ratings on the stock and zero issuing sell ratings. Recent ratings from UBS, Needham, and Barclays have all been positive, with various firms reiterating buy or overweight positions on $STZ. Moreover, multiple analysts have put forth price targets for $STZ, with a median target of $201.0. Notably, analysts like Kaumil Gajrawala of Jefferies set a target price of $205.0, while Peter Grom from UBS echoed a similar target on 07/03/2025.